Adapted conditioning for stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a risk-adapted conditioning regimen (chemotherapy and/or radiation given before transplant) for people with certain blood cancers or bone marrow disorders who need a stem cell transplant from a donor. The goal is to tailor the conditioning strength to each patient’s risk, which may help improve outcomes and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have one of these conditions: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), or chronic lymphocytic leukemia (CLL), and you need a stem cell transplant.
- You have a suitable donor: a matched sibling, matched unrelated donor, haploidentical (half-matched) family donor, or a one-antigen mismatched unrelated donor.
- You are able to care for yourself (performance status of at least 70%).
- Your major organs (kidneys, liver, heart, lungs) work well enough, as shown by standard tests.
- You are not pregnant and do not have an active uncontrolled infection or active central nervous system (brain/spinal cord) disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial is testing a more targeted way to deliver radiation before a stem cell transplant, aiming to reduce side effects while helping the new cells engraft. It includes two different radiation doses, one for first-time transplant patients and another for those who have relapsed after a prior transplant.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.